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Abstract
Medial temporal lobe atrophy (MTA) is a recognized marker of Alzheimer’s disease (AD), however, it can be prominent in frontotem-
poral lobar degeneration (FTLD). There is an increasing awareness that posterior atrophy (PA) is important in AD and may aid the
differentiation of AD from FTLD. Visual rating scales are a convenient way of assessing atrophy in a clinical setting. In this study, 2 visual
rating scales measuring MTA and PA were used to compare atrophy patterns in 62 pathologically-confirmed AD and 40 FTLD patients.
Anatomical correspondence of MTA and PA was assessed using manually-delineated regions of the hippocampus and posterior cingulate
gyrus, respectively. Both MTA and PA scales showed good inter- and intrarater reliabilities (kappa  0.8). MTA scores showed a good
correspondence with manual hippocampal volumes. Thirty percent of the AD patients showed PA in the absence of MTA. Adding the PA
to the MTA scale improved discrimination of AD from FTLD, and early-onset AD from normal aging. These results underline the
importance of considering PA in AD diagnosis, particularly in younger patients where medial temporal atrophy may be less conspicuous.
© 2012 Elsevier Inc. All rights reserved.
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Alzheimer’s disease (AD) is the most common cause of
dementia (Hebert et al., 2003). Frontotemporal lobar degen-
eration (FTLD), although less prevalent overall, is almost as
common as AD in patients under the age of 65 years
(Harvey et al., 2003; Ratnavalli et al., 2002). AD and FTLD
are histopathologically distinct, with AD being character-
ized by extracellular amyloid plaques and intraneuronal
neurofibrillary tangles (Braak and Braak, 1991), and FTLD
by the presence of non-AD histological pathology, most
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doi:10.1016/j.neurobiolaging.2011.04.003commonly either tau-positive inclusions or ubiquitin-posi-
tive, TAR DNA-binding protein (TDP)-43-positive inclu-
sions (Cairns et al., 2007).
Clinically, AD and FTLD may present with overlapping
symptoms, in particular in the early stages of the disease.
AD typically presents with episodic memory impairment
which progresses to involve multiple cognitive domains
(McKhann et al., 1984). Less common “atypical” forms of
AD have been described in which memory is not the pri-
mary deficit. These patients may present with visuospatial
and visuoperceptual problems (Benson et al., 1988), while
others present with behavioral symptoms (Johnson et al.,
1999; Taylor et al., 2008), yet others have predominantly
language difficulties (Gorno-Tempini et al., 2008). Patients
with FTLD pathology may also present with a range of
different clinical symptoms, most commonly categorized
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and the progressive aphasias of semantic dementia (SD),
and progressive nonfluent aphasia (PNFA) (Neary et al.,
1998).
Structural brain changes (atrophy) mirror the pathologi-
cal patterns in these disease groups and can be visualized in
life using magnetic resonance imaging (MRI) (Likeman et
al., 2005). In AD, medial temporal lobe atrophy (MTA) on
MRI is frequently an early feature of the disease, with
greatest volume loss found in the hippocampus, entorhinal
cortex, amygdala, and parahippocampus (Basso et al., 2006;
Fox and Schott, 2004; Teipel et al., 2006). In FTLD, regions
most affected are the frontal and anterior temporal lobes in
bvFTD, left anterior temporal lobe in SD, and left perisyl-
vian fissure in PNFA (for a review see Seelaar et al., 2011).
Therefore, while the presence of MTA is an important
hallmark of AD and the new AD research criteria (Dubois et
al., 2007) propose that the presence of memory loss with
MTA are sufficient to make a diagnosis of prodromal AD,
MTA is also present in FTLD and normal aging (Chan et al.,
2001; Fjell et al., 2009; Frisoni et al., 1996; Galton et al.,
2001a, 2001b). An increasing number of studies emphasize
the presence of atrophy in posterior areas of the brain such
as precuneus and posterior cingulate gyrus in AD (Jones et
al., 2006; Karas et al., 2007). Atrophy in these regions has
further been suggested to be more of a feature of early-onset
AD (EOAD) than late-onset AD (LOAD) (Frisoni et al.,
2007; Ishii et al., 2005a; Shiino et al., 2008).
Visual rating scales are increasingly used to assess atro-
phy for routine clinical use (Scheltens et al., 1992, 1997).
The MTA scale has been shown to discriminate well be-
tween AD and healthy controls, and to predict the conver-
sion from mild cognitive impairment (MCI) to AD (Korf et
l., 2004; Scheltens et al., 1992, 1995). We have recently
eveloped a visual rating scale for posterior atrophy (PA),
hich includes the posterior cingulate gyrus, precuneus, and
arietal lobes.
Table 1
Subject demographics
Control
n 50
Age in years, mean (SD) 59.7 (11.3)
Gender, male/female 29/21
Sporadic/familial NA
MMSE, mean (SD)c 29.1 (1.1)
Age at onset in years, mean (SD) NA
Disease duration in years, mean (SD)d NA
Time to death in years, mean (SD)e NA
Scanner A/B/C/Df 14/27/8/1
Key: AD, Alzheimer’s disease; FTLD, frontotemporal lobar degeneration
a Analysis of variance.
b Fisher exact test.
c Available in: 15 controls, 53 AD, and 28 FTLD.
d Time between first symptoms (onset) and scan.
e Time between scan and death, available in: 53 AD and 35 FTLD.
f A, B, C, D: different 1.5 T Signa GE scanners.Because the new diagnostic criteria may be used for
clinical trials which specifically target AD pathology, it is
only with pathologically-proven cases that one can be sure
of the predictive value of different atrophy measures such as
MTA or PA ratings. The current study therefore aimed (1)
to assess the inter- and intrarater agreement of the MTA and
PA scale in a large cohort of pathologically-proven AD and
FTLD patients, and controls; (2) to investigate associations
between visual rating scores and manual volumetric mea-
sures; (3) to assess the utility of MTA and PA scales in
distinguishing between pathologically-confirmed AD and
controls as well as FTLD which may be misdiagnosed as
AD; and (4) to assess the discriminatory ability of visual
ratings according to age at onset.
2. Methods
2.1. Subjects
Patients were selected retrospectively from a database of
pathologically- and genetically-confirmed subjects. This
identified 152 subjects who had undergone volumetric mag-
netic resonance (MR) imaging: 62 patients with “definite”
AD (55 pathologically- and 7 genetically-confirmed) ac-
cording to National Institute of Neurological and Commu-
nicative Disorders and Stroke-Alzheimer’s Disease and Re-
lated Disorders Association (NINCDS-ADRDA) criteria
(McKhann et al., 1984), and 40 patients with FTLD (all
pathologically-confirmed). Fifty healthy age- and gender-
matched controls were also included. Subject demographics
are summarized in Table 1. All patients had attended the
Cognitive Disorders Clinic at the National Hospital for
Neurology and Neurosurgery, London, UK. Informed con-
sent was obtained from all subjects and the study had local
ethics committee approval. We excluded subjects with
mixed AD and dementia with Lewy bodies (DLB) pathol-
ogy. Patients underwent comprehensive clinical assessment
AD FTLD p
62 40 NA
58.2 (10.6) 59.2 (8.9) 0.7a
34/28 26/14 0.6b
44/18 27/13 0.8b
17.2 (6.8) 22.9 (5.2) 0.0001a
54.1 (10.8) 55.0 (8.7) 0.7a
3.9 (2.9) 4.2 (2.1) 0.6a
5.6 (2.8) 6.4 (3.3) 0.3a
7/37/15/3 1/26/9/4 0.02b
, Mini-Mental State Examination; NA, not applicable.; MMSE
h
c
r
e
g
1
s
w
v
d
a
s
w
a
g
627.e3M. Lehmann et al. / Neurobiology of Aging 33 (2012) 627.e1–627.e12which included the Mini-Mental State Examination
(MMSE) (Folstein et al., 1975). The clinical notes were
retrospectively reviewed by a neurologist to determine
whether the clinical presentation was predominantly an am-
nestic, behavioral, language presentation, or a posterior cor-
tical atrophy (PCA) syndrome, characterized by deficits in
higher visual processing skills, calculation, and/or praxis.
2.2. MRI acquisition and processing
T1-weighted volumetric MR scans were performed on
1.5 Tesla Signa units (General Electric, Milwaukee, WI,
USA) using a volumetric spoiled gradient recalled (SPGR)
sequence with 1.5-mm thick slices covering the head. All
scans were spatially normalized into Montreal Neurological
Institute (MNI) 305 atlas space (Mazziotta et al., 1995) with
a 6 degrees-of-freedom (dof) registration.
2.3. Regional volumes in subset of subjects
Manual delineations of the hippocampus and posterior
cingulate gyrus had been obtained in a subset of 38 subjects
(11 controls, 19 AD, 8 FTLD, matched for age and gender)
as part of a previous study (Barnes et al., 2007). Demo-
graphic details as well as manual delineation protocols are
described in Barnes et al. (2007). Volumes in mm3 were
measured and analyzed separately for the left and right
hemisphere. Total intracranial volumes (TIVs) were also
available for the same subjects derived according to a pre-
viously described protocol (Whitwell et al., 2001).
2.4. Visual rating scales
All scans were assessed by 2 raters (EK and ML) blinded
to diagnoses and clinical information. MTA and PA were
rated once by each rater for the whole cohort (152 subjects),
and twice for the subset of 38 subjects for which there were
cingulate and hippocampal volumes available.
2.4.1. MTA scale
MTA was assessed using a standardized scale (Scheltens
et al., 1992). T1-weighted images were viewed in the cor-
onal plane and scores for the left and right hemispheres
were recorded. The scale rates atrophy on a 5-point scale
(0  absent, 1  minimal, 2  mild, 3  moderate, and
4  severe) based on the height of the hippocampal forma-
tion and the width of the choroid fissure and the temporal
horn.
2.4.2. PA scale
PA was scored on T1-weighted images viewed in the
sagittal, axial, and coronal planes. Separate scores for the
left and right hemispheres were obtained. The following
anatomical features were rated in 3 different orientations:
(1) Sagittal plane: Evaluation of widening of the posterior
cingulate and parieto-occipital sulcus, and atrophy of
the precuneus in the paramedian-sagittal plane; g(2) Axial plane: Evaluation of widening of the posterior
cingulate sulcus and sulcal dilatation in the parietal
lobes; and
(3) Coronal plane: Evaluation of widening of the posterior
cingulate sulcus and parietal sulci.
The PA scale rates atrophy on a 4-point scale: Grade 0
represents closed posterior cingulate and parieto-occipital
sulci and closed sulci of the parietal lobes and precuneus
(Fig. 1A); Grade 1 includes a mild widening of the posterior
cingulate and parieto-occipital sulci, with mild atrophy of
the parietal lobes and precuneus (Fig. 1B); Grade 2 shows
substantial widening of the posterior cingulate and parieto-
occipital sulci, with substantial atrophy of the parietal lobes
and precuneus (Fig. 1C); and Grade 3 represents end-stage
atrophy with evident widening of the posterior cingulate and
parieto-occipital sulci and knife-blade atrophy of the pari-
etal lobes and precuneus (Fig. 1D). When there was a
difference between scores in the different planes (e.g., score
1 for the sagittal view and score 2 for the axial view), the
highest score was given.
2.5. Statistical analysis
All statistical analyses were performed using Stata ver-
sion 11 (Stata Corp., College Station, TX, USA). A flow
chart showing which subjects were used for the different
parts of the analysis is presented in Fig. 2.
2.5.1. Inter- and intrarater reliability
Interrater reliability between the 2 raters for the MTA
and PA scales was assessed using scores from the whole
cohort of 152 subjects whereas intrarater reliability for both
scales was assessed in the subset of 38 subjects. Reliability
was measured using quadratically weighted kappas (Cohen,
1968). Bias-corrected and accelerated 95% bootstrap con-
fidence intervals (CI) for kappa were found using 10,000
bootstrap samples.
2.5.2. Anatomical correlates
Relationships between volumes and rating scores were
assessed by calculating mean volumes (in mm3) and SDs of
ippocampal volumes for each MTA grade, and posterior
ingulate gyrus volumes for each PA grade. Ratings of both
aters were averaged, resulting in half grades (i.e., 0.5, 1.5,
tc.). In order to ensure reasonable subject numbers for each
rade, volumes were averaged for Grades 0 and 0.5, 1 and
.5, 2 and 2.5, and all  3. Furthermore, MTA and PA
cores were dichotomized into normal and abnormal scores,
ith a score of  1 being considered abnormal. Mean
olumes for normal and abnormal scores as well as percent
ifferences between normal and abnormal are presented. To
ssess whether differences between grades were statistically
ignificant, an ordinal logistic regression was performed
ith the rating score (MTA and PA) as dependent variable
nd corresponding volume (hippocampal and posterior cin-
ulate gyrus) as independent variable, adjusting for age,
ender, and TIV.
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MTA and PA rating scores were first analyzed in
pathologically-confirmed sporadic AD (n  44) and com-
pared with pathologically-confirmed sporadic FTLD (n 
27) and controls (see Fig. 2). In order to assess the effect
of age at onset on visual ratings, the sporadic AD group
was split into pathologically-confirmed EOAD (age of
onset  65 years, n  33) and pathologically-confirmed
LOAD (age of onset  65 years, n  11), and compared
with younger (n  33) and older controls (n  14),
matched for age at time of scan and gender to the EOAD
and LOAD groups, respectively. Differences between
Fig. 1. T1-weighted sagittal, axial, and coronal images as examples for eac
1  minimal atrophy; (C) Grade 2  moderate atrophy; and (D) Grade
parieto-occipital sulcus; PRE, precuneus.early- and late-onset FTLD patients were not examinedbecause the number of late-onset FTLD was too small
(n  4) to conduct a meaningful comparison.
2.5.3.1. Atrophy patterns. Mean scores and SDs of MTA
and PA ratings were calculated and differences in scores
between groups were assessed using a Mann-Whitney/Wil-
coxon rank-sum test. MTA and PA scores were further
dichotomized into normal and abnormal, with a score of1
being considered abnormal. Ratings of both raters were
averaged.
2.5.3.2. Classification analysis and added value. In order
to assess the diagnostic accuracy of the MTA and PA scales
of the posterior atrophy (PA) scale. (A) Grade 0  no atrophy; (B) Grade
vere atrophy. PAR, parietal lobe; PCS, posterior cingulate sulcus; POS,h grade
3  sefor discriminating between groups, we estimated the area
627.e5M. Lehmann et al. / Neurobiology of Aging 33 (2012) 627.e1–627.e12under the receiver operator curve (ROC), denoted AUC.
The AUC measures the ability of a score to discriminate
between groups, and ranges from 0.5 (no predictive value)
to 1 (perfect discrimination). The added value of MTA and
PA was assessed by combining MTA and PA in a logistic
regression model. Differences in AUCs between combined
and single rating scales are reported as well as 95% Wald-
type CIs (1000 bootstrap samples) and p-values based on a
z-test of the difference in AUCs, using the bootstrap stan-
dard error. This was performed with the user-written Stata
command comproc (Janes et al., 2009). These analyses were
also based on the average of ratings from 2 raters.
3. Results
3.1. Subjects
Subject demographics are presented in Table 1. Of the 62
AD patients, 48 had a postmortem confirmation of AD, 7
had had a brain biopsy, and 7 had diagnostic genetic testing
alone. The AD group consisted of 44 sporadic cases, and 18
familial cases. All sporadic AD patients had pathological
confirmation of disease. Of the 44 sporadic AD cases, 19
patients had a typical amnestic presentation during life,
whereas 10 had a PCA syndrome, 9 had a language presen-
tation, and 4 had a behavioral presentation. There were
insufficient clinical details to determine the presenting clin-
ical features for 2 subjects. Furthermore, of the 44 sporadic
cases, 33 patients had an age at onset  65 years (EOAD),
whereas 11 had an age at onset of  65 years (LOAD). All
of the familial AD subjects had an amnestic presentation
during life. Of the 18 familial AD subjects, 11 had both
genetic testing and postmortem confirmation of disease, and
7 had a genetic diagnosis only. The familial AD cohort
Fig. 2. Overview of subject groups included for each analysis. EOAD, e
familial frontotemporal lobar degeneration; LOAD, late-onset Alzheimer’s
lobar degeneration.comprised 9 individuals with a presenilin 1 mutation and 8with an amyloid precursor protein (APP) gene. One indi-
vidual had pathologically-confirmed AD but screened neg-
ative for mutations currently known to cause familial AD.
As she had a strong family history suggesting autosomal
dominant inheritance of AD and a very young age at symp-
tom onset of 36, this subject was included in the familial
cohort.
Of the 40 FTLD patients included in this study, 36 had
postmortem confirmation of FTLD, and 4 had a brain bi-
opsy. Twenty of the FTLD cases had a behavioral syndrome
during life, and 20 had a language-led clinical presentation.
Twenty-seven patients were sporadic cases, whereas 13 had
a family history of FTLD. Of the 27 sporadic cases, 9 were
tau-positive (Pick’s pathology) and 18 were tau-negative
(13 TDP1, 3 ubiquitin-positive with unknown TDP status, 1
with neuronal intermediate filament inclusion disease
[NIFID], and 1 with dementia lacking distinctive histology
[DLDH]). Twenty-three had an age of onset 65 years, and
4 had an age of onset of  65 years. Of the 13 familial
cases, 7 were tau-positive and 6 were ubiquitin-positive (5
TDP43-positive and 1 TDP43-negative). Seven familial pa-
tients had a microtubule-associated protein tau (MAPT)
mutation, 3 had a progranulin (PGRN) mutation, and in 3
subjects with a history suggestive of FTLD a genetic mu-
tation was not identified.
There was no evidence of differences across the 3 main
groups (controls, AD, FTLD) for age and gender, and for
the FTLD and AD groups no significant difference in dis-
tribution of sporadic and familial cases, age of disease
onset, disease duration, or time to death (Table 1). However,
the AD subjects had a lower MMSE than the FTLD group
(p  0.0001). Scanner distribution (i.e., number of scans
from different scanners used in each group) was not signif-
set Alzheimer’s disease; FAD, familial Alzheimer’s disease; famFTLD,
e; spAD, sporadic Alzheimer’s disease; spFTLD, sporadic frontotemporalarly-on
diseasicantly different between AD and FTLD (p  0.3), how-
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A compared with AD and FTLD (p  0.02).
There was no significant difference in age or gender
between sporadic EOAD (mean age [SD]: 58.8 [6.6] years,
61% male) and younger controls (mean age [SD]: 56.5 [7.3]
years, 58% male). Similarly, there was no evidence of a
difference in age or gender between LOAD (mean age [SD]:
73.0 [5.4] years, 64% male) and older controls (mean age
[SD]: 72.7 [5.0] years, 64% male). The EOAD and LOAD
groups had a mean MMSE score of 16.7 and 19.1, respec-
tively (p  0.5), and a mean disease duration of 4.2 years
and 2.8 years, respectively (p  0.02).
3.2. Inter- and intrarater reliability
Both the MTA and PA scales had good inter- and intra-
rater reliability. Interrater kappa scores for the MTA scale
were 0.88 for left, 0.86 for right, and 0.91 for mean of both
hemisphere scores (Table 2). Interrater kappa scores for the
PA scale were 0.83 for left, 0.82 for right, and 0.84 for mean
of left and right hemisphere scores. Intrarater kappa scores
ranged from 0.83 to 0.91 for the MTA, and from 0.87 to
0.89 for the PA scale.
3.3. Anatomical correlates
Higher MTA scores were associated with smaller hip-
pocampal volumes in both hemispheres (p  0.001, Table
3). Lower posterior cingulate gyrus volumes were associ-
ated with higher PA ratings, which was statistically signif-
icant in the right hemisphere (p  0.004), but not in the left
Table 2
Inter- and intrarater kappa scores (95% CI) for MTA and PA scale
Scale Side Interrater (n
MTA LH 0.88 (0.84,
RH 0.86 (0.80,
Mean LH and RH 0.91 (0.87,
PA LH 0.83 (0.76,
RH 0.82 (0.75,
Mean LH and RH 0.84 (0.77,
Key: CI, confidence interval; LH, left hemisphere; MTA, medial tempora
Table 3
Volumes of hippocampus per MTA grade, and posterior cingulate gyrus p
Gradea Hpc volumes per MTA grade
LH RH
n Mean (SD) n Me
0 and 0.5 19 2598 (534) 18 273
1 and 1.5 9 2182 (403) 12 241
2 and 2.5 5 1892 (196) 7 211
 3 5 1985 (526) 1 148
Mean volumes and SDs are shown in mm3.
ey: Hpc, hippocampus; LH, left hemisphere; MTA, medial temporal l
emisphere.
a Mean of grades from 2 raters.hemisphere (p  0.3). Comparing the proportion of ex-
plained variation (R2) in posterior cingulate volumes for PA
atings versus dichotomized (present/absent) PA scores re-
ealed that the actual PA ratings explain relatively little
ariability in volumes over and above that explained by the
resent/absent PA ratings.
Mean hippocampal volume of subjects with abnormal
TA scores ( 1.5) was 21.0% lower than for those with
ormal MTA scores in the left hemisphere (1992 mm3
versus 2520 mm3), and 17.5% lower in the right hemisphere
(2214 mm3 versus 2685 mm3). Similarly, dichotomizing PA
cores into normal and abnormal, mean posterior cingulate
yrus volume of subjects with abnormal PA scores was
1.7% lower than for those with normal PA ratings in the
eft (1936 mm3 for abnormal and 2471 mm3 for normal),
and 23.3% lower in the right hemisphere (2149 mm3 for
abnormal and 2800 mm3 for normal).
3.4. Visual ratings in AD and FTLD
3.4.1. Atrophy patterns
MTA ratings were significantly greater in the FTLD
group compared with controls (p  0.0001) and compared
with AD (p  0.002 for left hemisphere; p  0.03 for mean
eft and right, Table 4). MTA ratings were also significantly
igher in the AD group compared with controls (p 
.0001). Ratings for the PA scale were greater in the AD
roup compared with controls (p  0.001) and FTLD (p 
.004 for right hemisphere; p  0.02 for mean left and
right). PA ratings were also significantly higher in the FTLD
) Intrarater (n  38)
Rater 1 Rater 2
0.90 (0.84, 0.96) 0.91 (0.84, 0.96)
0.87 (0.77, 0.94) 0.83 (0.71, 0.92)
0.90 (0.83, 0.95) 0.90 (0.83, 0.95)
0.88 (0.77, 0.96) 0.88 (0.74, 0.96)
0.88 (0.78, 0.95) 0.87 (0.74, 0.95)
0.89 (0.79, 0.95) 0.88 (0.76, 0.96)
trophy; PA, posterior atrophy; RH, right hemisphere.
grade
PCG volumes per PA grade
LH RH
) n Mean (SD) n Mean (SD)
18 2449 (685) 17 2809 (459)
14 2197 (818) 13 2591 (798)
6 2021 (520) 8 1900 (540)
0 — 0 —
ophy; PA, posterior atrophy; PCG, posterior cingulate gyrus; RH, right 152
0.92)
0.90)
0.93)
0.88)
0.87)
0.89)er PA
an (SD
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.03).
Dichotomizing MTA and PA scores into normal and
bnormal revealed different patterns of atrophy in each
roup (Table 5). The majority (72%) of the control subjects
ad normal atrophy scores (i.e., normal MTA and PA); 30%
f the AD patients had PA in the absence of abnormal MTA
i.e., abnormal PA, normal MTA), whereas only 7% of the
TLD group had abnormal PA score and normal MTA.
ixty-three percent of the FTLD patients had a normal PA
ith an abnormal MTA score. The demographic data for the
different AD subgroups (i.e., no atrophy, MTA only, PA
nly, both MTA and PA; see Supplementary Table 1) fur-
her show that the PA only AD group is slightly younger in
ge than AD subjects with MTA only, however, this differ-
nce was not statistically significant.
.4.2. Classification analysis
While discrimination abilities for separating AD from con-
rol subjects were good for both MTA and PA scales (AUC
.80 and 0.74, respectively, for mean left and right), they
mproved significantly when combining both scales (0.87
ean left and right, Table 6). In contrast, adding the PA to the
TA scale did not improve accuracy for separating FTLD
rom controls (p  0.4). For the discrimination between AD
nd FTLD, combining both scales improved classification ac-
uracy to 0.73 (mean left and right), although the differences
ere not statistically significant. The greatest improvement
as found in the right hemisphere, where adding the PA to the
TA scale significantly increased accuracy to 0.72 (p 0.02).
Table 4
Mean and SD of MTA and PA scores in control, AD, and FTLD and p v
groups
Scale Side Control (n  50) AD (n  44)
Mean (SD) Mean (SD)
MTA LH 0.44 (0.58) 1.43 (1.08)
RH 0.37 (0.56) 1.24 (0.98)
Mean LH and RH 0.41 (0.53) 1.34 (0.95)
PA LH 0.77 (0.64) 1.40 (0.83)
RH 0.77 (0.68) 1.45 (0.81)
Mean LH and RH 0.77 (0.62) 1.43 (0.77)
Key: AD, Alzheimer’s disease; FTLD, frontotemporal lobar degeneration;
RH, right hemisphere.
Table 5
Different atrophy patterns in control, AD, and FTLD
Control AD FTLD
No atrophy 72% 18% 4%
MTA only 6% 18% 63%
PA only 18% 30% 7%
MTA and PA 4% 34% 26%
Shown are proportion of subjects in percent who had no atrophy, MTA
only, PA only, and both MTA and PA.
Key: AD, Alzheimer’s disease; FTLD, frontotemporal lobar degeneration;pMTA, medial temporal lobe atrophy; PA, posterior atrophy..5. The effect of onset on visual ratings in AD
.5.1. Atrophy patterns in EOAD and LOAD
Both EOAD and LOAD showed significantly higher MTA
cores compared with younger and older controls, respectively,
ith MTA scores being significantly higher in LOAD than
OAD (p  0.02 for right, p  0.04 for mean left and right,
able 7). In addition, EOAD showed significantly greater PA
cores compared with younger controls (p 0.0001), whereas
o significant difference in PA scores between LOAD and
lder controls was found.
Dichotomizing MTA and PA scores into normal and ab-
ormal revealed that over 1 third of EOAD patients (33%) had
A only (Table 8). Of the LOAD patients, all had some
bnormal atrophy score with almost half of the LOAD patients
aving MTA only (46%). The majority of the younger controls
81%) had no atrophy, whereas almost half of the older con-
rols (43%) had either MTA, PA, or both MTA and PA. These
ata suggest that abnormal PA scores may be more useful in
ounger patients and may be less specific in elderly people.
.5.2. Classification analysis
Combining MTA and PA ratings significantly improved
he separation of EOAD from younger controls to 0.89
mean left and right, Table 9). In contrast, adding the PA to
he MTA scale did not significantly improve separation of
OAD from older controls (p 0.5 for mean left and right),
hereas adding the MTA to the PA scale did result in a
etter separation (p  0.01 for mean left and right). Dis-
riminatory ability of the MTA scale was higher for the
eparation of LOAD from older controls than EOAD from
ounger controls, whereas the PA scale showed a better
iscrimination for the EOAD from younger control classi-
cation than LOAD versus older controls. While these dif-
erences were not statistically significant, the magnitude of
hese differences, in particularly for the PA scale, was
elatively high.
. Discussion
This study demonstrates that in addition to medial tem-
om Wilcoxon rank-sum test comparing distribution of scores between
(n  27) Control vs. AD Control vs. FTLD AD vs. FTLD
(SD) p p p
.13) 0.0001 0.0001 0.002
.00) 0.0001 0.0001 0.7
.89) 0.0001 0.0001 0.03
.67) 0.0002 0.03 0.2
.65) 0.0001 0.3 0.004
.62) 0.0001 0.1 0.02
t hemisphere; MTA, medial temporal lobe atrophy; PA, posterior atrophy;alues fr
FTLD
Mean
2.37 (1
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Furthermore, in a subset of patients with pathologically-
proven AD, posterior atrophy may be present in the absence
of marked atrophy in the medial temporal lobes. Because
atrophy in the medial temporal lobes is a suggested marker
for AD in new diagnostic criteria, a substantial proportion of
AD patients may be misdiagnosed as normal if only this
area is considered. Furthermore, MTA is also common in
FTLD which may lead to misdiagnosis of FTLD patients as
AD. However, PA is less common in FTLD, making it a
potentially useful marker to separate AD and FTLD pa-
tients. In our study we show that the presence of posterior
atrophy helps to distinguish AD from FTLD, and also helps
separate early-onset AD patients (onset  65 years) from
ounger controls. This study, with the strength of patholog-
cal confirmation in all patients, therefore suggests that the
resence of posterior atrophy may be a useful additional
arker of AD pathology, over and above MTA. Our inves-
igation further presents and establishes a tool with which
osterior atrophy can be easily and reliably assessed in a
linical setting.
Nonmemory related deficits such as visuospatial prob-
ems are increasingly recognized as being a feature of AD
Table 6
AUCs for classification of control, AD, and FTLD
Group Side MTA PA MTA and
AUC AUC AUC
vs. AD LH 0.77 0.72 0.86
RH 0.76 0.74 0.83
Mean LH and RH 0.80 0.74 0.87
vs. FTLD LH 0.92 0.65 0.92
RH 0.81 0.57 0.80
Mean LH and RH 0.93 0.61 0.92
D vs. FTLD LH 0.72 0.60 0.74
RH 0.53 0.70 0.72
Mean LH and RH 0.66 0.66 0.73
ata are for single and combined rating scales, as well as differences in A
nd p values.
ey: AD, Alzheimer’s disease; AUC, area under the receiver operator cu
TA, medial temporal lobe atrophy; PA, posterior atrophy; RH, right he
able 7
eans and SDs of MTA and PA scores in younger and older controls, E
f scores between groups
Group and comparison MTA
LH RH
ounger controls (n  33), mean (SD) 0.38 (0.53) 0.29 (0.43)
OAD (n  33), mean (SD) 1.29 (1.04) 1.05 (0.95)
ounger controls vs. EOAD, p 0.0002 0.001
lder controls (n  14), mean (SD) 0.68 (0.67) 0.64 (0.77)
OAD (n  11), mean (SD) 1.86 (1.12) 1.82 (0.87)
lder controls vs. LOAD, p 0.01 0.003
OAD vs. LOAD, p 0.1 0.02
ey: EOAD, early-onset Alzheimer’s disease; LH, left hemisphere; LO
osterior atrophy; RH, right hemisphere.(van der Flier et al., 2011). It is perhaps therefore not
surprising that an anatomical correlate of visuospatial def-
icits, namely posterior atrophy, is useful in distinguishing
AD from FTLD. The involvement of posterior brain regions
in AD seen in this study is in accordance with previous
reports showing that AD is not only characterized by atro-
phy of the medial temporal lobe but also of posterior regions
such as precuneus and posterior cingulate gyrus (Barnes et
al., 2007; Frisoni et al., 2007; Galton et al., 2000). Posterior
hypometabolism has long been recognized to be character-
istic of AD (Ishii et al., 2005b; Minoshima et al., 1997).
Posterior regions have also been shown to have higher
levels of amyloid deposition early in AD (Kemppainen et
al., 2007; Klunk et al., 2004). Functional imaging studies
have further shown that the default-mode network, which
includes medial temporal lobe regions and posterior re-
gions, is also affected early in AD (Greicius et al., 2004;
Zhang et al., 2010).
Both the MTA and PA scales showed reasonable inter-
and intrarater kappa scores. Higher MTA scores further
corresponded with smaller hippocampal volumes, similar to
previous studies (Bresciani et al., 2005; Scheltens et al.,
1992; Wahlund et al., 2000). The difference in hippocampal
Adding PA to MTA p Adding MTA to PA p
Difference (95% CI) Difference (95% CI)
0.08 (0.01–0.16) 0.02 0.14 (0.05–0.23) 0.002
0.06 (0.00–0.16) 0.07 0.09 (0.02–0.16) 0.01
0.07 (0.01, 0.14) 0.03 0.13 (0.04, 0.22) 0.004
0.00 (0.02 to 0.02) 1.0 0.28 (0.15–0.40) 0.001
0.01 (0.04 to 0.03) 0.7 0.23 (0.08–0.39) 0.003
0.01 (0.03 to 0.01) 0.4 0.30 (0.17–0.44) 0.001
0.02 (0.03–0.08) 0.5 0.15 (0.02–0.28) 0.03
0.19 (0.02–0.35) 0.02 0.02 (0.05–0.08) 0.6
0.08 (0.02–0.17) 0.1 0.07 (0.03–0.18) 0.2
etween combined and single rating scales, 95% confidence intervals (CI)
control; FTLD, frontotemporal lobar degeneration; LH, left hemisphere;
e.
d LOAD, p values from Wilcoxon rank-sum test comparing distribution
PA
an LH and RH LH RH Mean LH and RH
3 (0.44) 0.65 (0.58) 0.71 (0.56) 0.68 (0.53)
7 (0.92) 1.42 (0.79) 1.45 (0.81) 1.44 (0.76)
001 0.0001 0.0001 0.0001
6 (0.69) 1.14 (0.66) 1.07 (0.85) 1.11 (0.72)
4 (0.88) 1.32 (0.96) 1.45 (0.85) 1.39 (0.84)
02 0.7 0.3 0.5
4 0.7 0.8 0.7
e-onset Alzheimer’s disease; MTA, medial temporal lobe atrophy; PA,PA
UCs b
rve; C,OAD an
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1.1
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relatively high, with the mean of abnormal volumes being
21.0% lower in the left and 17.5% lower in the right hemi-
sphere than the mean of normal volumes, with on average a
1 point rise in MTA score being equivalent to around 12%
reduction in hippocampal volume. It should be noted, how-
ever, that this difference is determined by the cutoff score
used to define normal and abnormal MTA. It has been
shown that an appropriate cutoff score is age-dependent,
with a score of  1 being considered abnormal below the
ge of 75, whereas in patients  75 years of age a score of
 2 would be required to identify abnormal MTA (Schel-
tens et al., 1992). Duara et al. showed that a mean MTA
score of 1.33 produced optimal sensitivities and specificities
to separate patients with AD and mild cognitive impairment
(MCI) from healthy controls (Duara et al., 2008). Using
postmortem MRI of very old AD patients ( 85 years),
arkhof et al. showed that a cutoff score of 2 correctly
xcluded subjects with no or borderline Alzheimer-type
athology (Barkhof et al., 2007). Because the AD group in
he current study is relatively young (mean age 58 years), a
utoff score of  1 was used to define abnormal MTA. To
nsure consistency the same cutoff score was used for the
A scale. Higher PA scores only roughly corresponded with
maller volumes of the posterior cingulate gyrus, probably
Table 8
Different atrophy patterns in younger and older controls, EOAD, and
LOAD
Younger
controls
Older
controls
EOAD LOAD
No atrophy 81% 43% 24% 0%
MTA only 3% 14% 9% 46%
PA only 12% 36% 33% 18%
MTA and PA 3% 7% 33% 36%
Data are proportion of subjects in percent who had no atrophy, MTA only,
PA only, and both MTA and PA.
Key: EOAD, early-onset Alzheimer’s disease; LOAD, late-onset Alzhei-
mer’s disease; MTA, medial temporal lobe atrophy; PA, posterior atrophy.
Table 9
AUCs for classification of younger and older controls, EOAD and LOAD
Group Side MTA PA M
AUC AUC A
ounger controls vs. EOAD LH 0.75 0.77 0
RH 0.74 0.77 0
Mean LH and RH 0.77 0.78 0
lder controls vs. LOAD LH 0.81 0.55 0
RH 0.85 0.61 0
Mean LH and RH 0.87 0.58 0
OAD vs. LOAD LH 0.65 0.54 0
RH 0.73 0.52 0
Mean LH and RH 0.71 0.54 0
hown are single and combined rating scales, and differences in AUCs b
alues.
ey: AUC, area under the receiver operator curve; EOAD, early-onset Alzobe atrophy; PA, posterior atrophy.ecause the PA scale reflects more than just posterior cin-
ulate atrophy. Although there was only evidence of an
ssociation in the right hemisphere, a test for interaction
howed no evidence that the association differs by hemi-
phere (p  0.1).
The presence of MTA in the FTLD group underlines
he fact that hippocampal atrophy is not exclusive to AD,
ut has been widely described in FTLD as well (Chan et
l., 2001; Galton et al., 2001a, 2001b; Mesulam, 2001;
hompson et al., 2003). Posterior atrophy scores, on the
ther hand, were significantly higher in the AD group
ompared with FTLD. This difference was driven by
reater posterior atrophy in the right hemisphere in AD.
t is perhaps surprising that a proportion of FTLD cases
ave quite prominent posterior atrophy in the left hemi-
phere. This is likely to be due to the language cases in
his group where left-sided atrophy can spread posteri-
rly as the disease progresses. Higher PA ratings in the
ight hemisphere in AD significantly improved the dis-
inction of AD from FTLD. It should be noted, however,
hat average scores of 2 raters were used in this study.
lassification accuracies therefore may not necessarily
eflect performance of a single rater.
Interestingly, 30% of AD subjects in this study had marked
A in the absence of an abnormal MTA rating, whereas only
8% showed the opposite pattern. The AD patients with PA
nly tended to be younger (in terms of age and onset) than
atients with MTA only. Splitting the AD group into early- and
ate-onset patients further revealed that PA ratings significantly
mproved the classification of EOAD from younger control
ubjects, whereas it did not improve the separation between
OAD and older control subjects. This suggests that atrophy in
osterior regions of the brain is particularly important to con-
ider when making a diagnosis in early-onset patients. How-
ver, this segregation with age is not exclusive; some younger
D patients may present with mostly MTA, while some
OAD may have mostly PA.
d PA Adding PA to MTA Adding MTA to PA
Difference (95% CI) p Difference (95% CI) p
0.11 (0.02–0.21) 0.02 0.09 (0.01–0.17) 0.03
0.10 (0.00–0.20) 0.05 0.07 (0.01–0.14) 0.07
0.11 (0.02–0.21) 0.02 0.10 (0.01–0.20) 0.03
0.07 (0.06–0.21) 0.3 0.34 (0.09–0.60) 0.01
0.02 (0.10–0.14) 0.8 0.26 (0.04–0.48) 0.02
0.04 (0.07–0.14) 0.5 0.33 (0.09–0.57) 0.01
0.01 (0.12–0.10) 0.9 0.11 (0.10–0.32) 0.3
0.03 (0.07–0.13) 0.5 0.24 (0.02–0.46) 0.03
0.02 (0.10–0.07) 0.7 0.15 (0.06–0.36) 0.2
combined and single rating scales, 95% confidence intervals (CI), and p
’s disease; LOAD, late-onset Alzheimer’s disease; MTA, medial temporal,
TA an
UC
.86
.84
.89
.89
.87
.91
.65
.76
.69
etween
heimer
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tion. It is unclear how MTA and PA ratings are affected by
different scan acquisition protocols and quality. However, it
has been shown that MTA ratings are comparable using
MRI and computed tomography (CT) (Wattjes et al., 2009).
Furthermore, the fact that strong patterns were still detected
in different groups suggests that visual rating tools are
relatively robust to varying image quality. It should fur-
ther be noted that only sporadic AD and FTLD cases
were included in the group comparison and classification
analyses. This was motivated by the fact that the familial
AD cases were significantly younger than the sporadic
AD cases (mean age 47.7 [SD 6.4] for familial AD and
62.3 [SD 8.9] for sporadic AD), and that previous studies
suggesting that familial AD patients can have a different
clinical phenotype and different patterns of amyloid ac-
cumulation than sporadic AD cases (Knight et al., 2011;
Ryan and Rossor, 2010). The exclusion of the familial
cases therefore resulted in more homogenous groups for
the group comparison analysis. While some of these AD
patients had nonamnestic clinical presentations during
life and may therefore be considered as “atypical”, all of
these patients had pathological confirmation of disease.
Because pathological confirmation remains the gold stan-
dard to establish a definite diagnosis of AD, and because
potential interventional treatments are likely to specifi-
cally target AD pathology, the main objective of the
current study was to assess visual ratings in patients with
AD pathology irrespective of clinical diagnosis. Further
investigations assessing the relative utility of the visual assess-
ment tools presented in this study should be performed in
clinically-diagnosed older sporadic AD patients.
In summary, the current study demonstrates pro-
nounced atrophy in posterior cerebral regions in the ab-
sence of clear atrophy in the medial temporal lobe in
patients with pathologically-confirmed AD. Because
MTA is currently a proposed diagnostic marker for AD,
these findings may suggest that some AD patients may
not receive a diagnosis of AD if only MTA is considered.
The presence of posterior atrophy may be a helpful ad-
ditional marker for AD, especially in younger patients.
This study further presents a tool with which posterior
cerebral atrophy can be easily and reliably assessed in a
clinical setting. Visual ratings of PA may improve diag-
nostic accuracy for distinguishing AD from FTLD, and
may be valuable in distinguishing early-onset AD from
younger control subjects.
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